Clinical outcome of Linezolid in the Treatment of Extensively Drug-resistant Tuberculosis in Beijing, China: A Hospital-based retrospective Study.

Clinical outcome of Linezolid in the Treatment of Extensively Drug-resistant Tuberculosis in Beijing, China: A Hospital-based retrospective Study. Jpn J Infect Dis. 2015 Jan 20; Authors: Liu Y, Bao P, Wang D, Li Y, Tang L, Zhou Y, Zhao W Abstract linezolid, showed good clinical outcome against multidrug-resistant (MDR) and extensively drug-resistant tuberculosis(XDR-TB) in some reports, but its efficacy in indiviual TB patients and its precise contribution to combination regimens remain unclear in Chinese patients. In this paper, we described our study conducted with the aim to further characterize clinical outcome and safety of linezolid in adults with XDR pulmonary TB in Chinese PLA 309 hospital. Totally 16 XDR-TB patients received linezolid 600 mg daily and vitamin B6 50-100 mg daily as part of their individualised treatment regimens. Of the 16 patients, 14 had a history of previous treatment for tuberculosis. All patients were heavily CFU counting in sputum samples tested by realtime-PCR and there was a high proportion of patients with cavitary lesions in the lungs. There were 11 (68.75%) of the 16 patients had successfully completed therapy, with documented negative qPCR data and cultures a mean follow-up of 12 months. Three patients (18.75%) are still receiving treatment, and all had clinical and radiographic improvement. Two patients were discontinued of linezolid with remaining qPCR or culture positive because both of them de...
Source: Japanese Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Jpn J Infect Dis Source Type: research